A Phase 4, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 4, Open-label, Long-term Study of SYR-472 (100 mg) in Combination With Insulin in Patients With Type 2 Diabetes

NCT02324569 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

240

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: SYR-472
DRUG: Placebo

Sponsor

Takeda